Fetal Lymphatic Dysplasia Targeted RASopathy Gene Panel Sequencing: Molecular Findings and Genotype-Phenotype Correlations
Fetal Diagnosis and Therapy · 2026-11-09
DOI: 10.1159/fdt/acuag030 ↗Abstract
Abstract Introduction: Prenatal diagnosis of lymphatic dysplasia (LD) remains difficult, especially in fetuses with normal karyotype and chromosomal microarray (CMA) results. This retrospective and prospective study (2022–2023) aimed to evaluate the contribution of RASopathy-associated gene analysis, as an advanced molecular test, to the etiology of pregnancies undergoing invasive testing for increased NT/NF and/or cystic hygroma when conventional cytogenetic and molecular karyotyping were normal. Methods: Twenty fetuses with ultrasound findings including cystic hygroma, increased nuchal translucency (NT ≥3.5 mm), and/or increased nuchal fold (NF ≥6 mm) were enrolled after normal karyotype and CMA analyses. DNA obtained from chorionic villus sampling or amniocentesis was analyzed using targeted next-generation sequencing of RASopathy-associated genes. Variants were interpreted according to ACMG/ACGS guidelines. Results: RASopathy-related variants were identified in 7 of 20 fetuses (35%). Pathogenic variants were detected in the HRAS, PTPN11, and RIT1 genes, while variants of uncertain significance were found in the MAP2K1, RAF1, MAP2K2, and SPRED1 genes. In cases with parental testing, pathogenic variants were confirmed as de novo. No clinically significant variants were identified in the remaining fetuses. Conclusion: These findings demonstrate that a considerable proportion of fetuses with idiopathic LD harbor RASopathy-related variants. Incorporating targeted RASopathy panels into prenatal evaluation may improve diagnosis, counseling, pregnancy management, and assessment of recurrence risk.
EUVIMED